This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on Web of Science (1)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Statistics and Research Methods  • Randomized Controlled Trial  • Alert me on articles by topic  Social Bookmarking   What's this?

Brian Vastag

JAMA. 2003;290:2115-2116.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

The National Institutes of Health (NIH) is "turbo-charging" with a 5-year, $2 billion plan to speed biological discoveries into blockbuster treatments. Designed to leverage leaps in biotechnology, the ambitious strategy aims to reveal the most fundamental workings of the body by encouraging and rewarding high-risk research. A vast network of community physicians is then envisioned to quickly test emerging therapies.

"Some say these initiatives are bold, maybe too bold," said Francis Collins, MD, PhD, director of the National Human Genome Research Institute. "Fifteen years ago they said the same thing about the Human Genome Project."

NIH ROADMAP

As NIH Director Elias Zerhouni, MD, PhD, unveiled the plan at a press conference, the heads of NIH's 27 institutes and centers congregated in an unprecedented display of solidarity. "We're removing roadblocks that all [NIH] institutes encounter but that none could solve alone," said Zerhouni. The year-long development of the . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?